EX-99.1 2 d108693dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Châtillon, France, June 29, 2026 ──────────────────────────────────── DBV Technologies Provides BLA Submission Update for the VIASKIN ® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing DBV has been engaged in extensive discussions with the FDA in preparation of its BLA for the VIASKIN® Peanut Patch in children aged four through seven years The objective of the detailed, iterative engagement was to ensure a complete, efficient, and timely FDA review of the BLA, once submitted The Agency has not requested additional data DBV will take additional time to incorporate the FDA feedback and anticipates submitting the BLA in the third quarter of 2026 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────── DBV will host a conference call today, June 29, at 5:00pm ET ──────────────────────────────────────────────────────────────── DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today provi…
Open exhibit ↗Current Report · Items 8.01, 9.01 · 8-K
DBV Technologies S.A.
DBVTFOTCEQUITYCurrent
Other Events
Item 8.01. Other Events On June 29, 2026, DBV Technologies S.A. (the “Company”) issued a press release entitled “DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 Through 7 Years;…
Company context
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® Patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® Peanut Patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of people with food allergies. The Company’s food allergy programs include ongoing clinical trials of VIASKIN® Peanut Patch in toddlers (1 through 3 years of age) and children (4 through 7 years of age) with peanut allergy.